BRCA1 and ovarian carcinoma: We show for the 1st time the feasibility and clinical usefulness of performing HRD testing encompassing both BRCA1/2 pathogenic variant analysis as well as genomic instability testing on cftDNA from peritoneal fluid obtained from patients with newly diagnosed advanced ovarian cancer.